78886-45-0

Usage

Uses

Used in Pharmaceutical Industry:
(4-METHYL-THIAZOL-2-YL)-HYDRAZINE is used as a potential intermediate or reagent for the development of new drugs, leveraging its unique chemical structure to contribute to medicinal chemistry advancements.
Used in Agricultural Chemicals:
In the agricultural sector, (4-METHYL-THIAZOL-2-YL)-HYDRAZINE may be utilized in the formulation of pesticides or herbicides, where its chemical properties could offer novel modes of action or enhanced efficacy in controlling pests and weeds.
Used in Chemical Production:
(4-METHYL-THIAZOL-2-YL)-HYDRAZINE is used as a potential component in the production of dyes, pigments, or other chemical products, where its specific attributes might provide new colorants or functional properties for various applications.

InChI:InChI=1/C4H7N3S/c1-3-2-8-4(6-3)7-5/h2H,5H2,1H3,(H,6,7)

Upstream product

• 17574-13-9 2-(2-acetylhydrazino)-4-methylthiazole 
• 79-19-6 thiosemicarbazide 
• 146942-59-8 3,4,5-Trimethoxy-benzoic acid N'-(4-methyl-thiazol-2-yl)-hydrazide 

Downstream Products

• 37072-50-7 2-benzylidenehydrazono-4-methylthiazole 

Relevant academic research and scientific papers

Discovery of potent anti-tuberculosis agents targeting leucyl-tRNA synthetase

Tuberculosis is a serious infectious disease caused by human pathogen bacteria Mycobacterium tuberculosis. Bacterial drug resistance is a very significant medical problem nowadays and development of novel antibiotics with different mechanisms of action is an important goal of modern medical science. Leucyl-tRNA synthetase (LeuRS) has been recently clinically validated as antimicrobial target. Here we report the discovery of small-molecule inhibitors of M. tuberculosis LeuRS. Using receptor-based virtual screening we have identified six inhibitors of M. tuberculosis LeuRS from two different chemical classes. The most active compound 4-{[4-(4-Bromo-phenyl)-thiazol-2-yl]hydrazonomethyl}-2-methoxy-6-nitro-phenol (1) inhibits LeuRS with IC50 of 6 μM. A series of derivatives has been synthesized and evaluated in vitro toward M. tuberculosis LeuRS. It was revealed that the most active compound 2,6-Dibromo-4-{[4-(4-nitro-phenyl)-thiazol-2-yl]-hydrazonomethyl}-phenol inhibits LeuRS with IC50 of 2.27 μM. All active compounds were tested for antimicrobial effect against M. tuberculosis H37Rv. The compound 1 seems to have the best cell permeability and inhibits growth of pathogenic bacteria with IC50 = 10.01 μM and IC90 = 13.53 μM.

Palladium-catalyzed cyclization of 3-propargylmercapto-1,2,4-triazine to thiazolo[2,3-c][1,2,4]triazine

Palladium(II)-catalyzed selective transformation of 3-propargylmercapto-1,2,4-triazin-5(2H)-one 1 to 6-methylene-6,7-dihydro-7 H-thiazolo[2,3-c][l,2,4]triazin-5-one 3 has been carried out. Under basic condition the latter is isomerized to a compound which is identified as 3,6-dimethyl-5 H-thiazolo[2,3-c][1,2,4]triazin-5-one 4. For definite structure assignment of 4, this compound has been synthesized unambiguously and its spectroscopic data have been compared with those of the isomerization product.

MAOI activity of some novel series of substituted thiazol-2-yl-hydrazines

Three series of 2-thiazolylhydrazines were synthetized and evaluated for their MAO inhibitory (MAOI) activity, both by in vivo tests, to assay their influence on several MAOI activity-related parameters (the variation on blood pressure induced by tyramine